Hemostatic effect of acylated ghrelin in control and sleeve gastrectomy-induced rats: mechanisms of action.
Acylation
Angiotensin II
/ pharmacology
Animals
Aorta
/ cytology
Blood Coagulation
/ drug effects
Drug Administration Schedule
Endothelial Cells
/ cytology
Fibrinogen
/ metabolism
Gastrectomy
/ methods
Gene Expression
/ drug effects
Ghrelin
/ analogs & derivatives
Hemostatics
/ pharmacology
Injections, Subcutaneous
Male
NG-Nitroarginine Methyl Ester
/ pharmacology
Nitric Oxide
/ antagonists & inhibitors
Nitric Oxide Synthase Type III
/ genetics
Oligopeptides
/ pharmacology
Plasminogen Activator Inhibitor 1
/ genetics
Platelet Aggregation
/ drug effects
Primary Cell Culture
Rats
Rats, Sprague-Dawley
Receptors, Ghrelin
/ antagonists & inhibitors
Thromboxane B2
/ metabolism
von Willebrand Factor
/ metabolism
Ghrelin
coagulation
fibrinolysis
platelet
rats
sleeve gastrectomy
Journal
Archives of physiology and biochemistry
ISSN: 1744-4160
Titre abrégé: Arch Physiol Biochem
Pays: England
ID NLM: 9510153
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
pubmed:
16
10
2018
medline:
24
3
2020
entrez:
16
10
2018
Statut:
ppublish
Résumé
This study investigated the effect of acylated ghrelin (AG) deficiency after sleeve gastrectomy (SG) or chronic administration in control and SG-indiuced rats on platelet function, coagulation, and fibrinolysis. Administration of AG (100 µg/kg, subcutaneously) to control or SG rats significantly inhibited platelets aggregation and lowered levels of Von-Willebrand factor (vWF), fibrinogen, and thromboxane B2. Concomitantly, it decreased circulatory levels and aortic expression levels of plasminogen activator inhibitor-1 (PAI-1) and tissue factor (TF) and increased the aortic expression of the endothelial nitric oxidase (eNOS). However, AG inhibited angiotensin-II (ANGII)-induced upregulation of tissue factor pathway inhibitor (TPAI) and TF and increased activity of TF and increases eNOS expression in cultured endothelial cells, an effect that was abolished by the addition of D-[lys3]-GHRP-6, a selective AG receptor (GHSR-1a) blocker or L-Name, a potent eNOS inhibitor. In conclusion, AG has an anti-platelet, anti-coagulant, and fibrinolytic roles mediated through GHSR-1a to enhance nitric oxide synthesis.
Identifiants
pubmed: 30320517
doi: 10.1080/13813455.2018.1489849
doi:
Substances chimiques
GHRP-6, Lys(3)-
0
Ghrelin
0
Ghsr1a protein, rat
0
Hemostatics
0
Oligopeptides
0
Plasminogen Activator Inhibitor 1
0
Receptors, Ghrelin
0
von Willebrand Factor
0
Angiotensin II
11128-99-7
Nitric Oxide
31C4KY9ESH
Thromboxane B2
54397-85-2
Fibrinogen
9001-32-5
Nitric Oxide Synthase Type III
EC 1.14.13.39
Nos3 protein, rat
EC 1.14.13.39
NG-Nitroarginine Methyl Ester
V55S2QJN2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM